Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

Michael B. Maris, Brenda M. Sandmaier, Barry E. Storer, Thomas Chauncey, Monic Jain Stuart, Richard Maziarz, Edward Agura, Amelia A. Langston, Michael Pulsipher, Rainer Storb, David G. Maloney

Research output: Contribution to journalArticle

218 Citations (Scopus)

Abstract

We carried out HLA-matched related (n = 16) and unrelated (n = 17) hematopoietic cell transplantation (HCT) in 33 patients with relapsed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy total body irradiation. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil. Fourteen patients had failed high-dose autologous HCT. Of the 33 patients studied, 31 had stable engraftment, whereas 2 patients experienced nonfatal graft rejections. The incidences of acute grades II, III, and IV, and chronic graft-versus-host disease (GVHD) were 27%, 17%, 13%, and 64%, respectively. The overall response rate in the 20 patients with measurable disease at the time of HCT was 85% (n = 17; 75% complete remissions [CR] and 10% partial remissions [PR]), whereas 3 patients had progressive disease. Only one of the 17 patients who responded and none of the 13 who received transplants in CR had disease relapse with a median follow-up of 24.6 months. Relapse and nonrelapse mortalities were 9% and 24%, respectively, at 2 years. The Kaplan-Meier probabilities of overall and disease-free survivals at 2 years were 65% and 60%, respectively. Allogeneic HCT after nonmyeloablative conditioning is a promising salvage strategy for patients with relapsed and refractory mantle cell lymphoma. The high response and low relapse rates with this approach suggest that mantle cell lymphoma is susceptible to graft-versus-tumor responses.

Original languageEnglish (US)
Pages (from-to)3535-3542
Number of pages8
JournalBlood
Volume104
Issue number12
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Whole-Body Irradiation
Cell Transplantation
Refractory materials
Irradiation
Grafts
Mycophenolic Acid
Salvaging
Transplants
Recurrence
Cyclosporine
Tumors
fludarabine
Graft Rejection
Graft vs Host Disease
Immunosuppression
Disease-Free Survival
Mortality
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. / Maris, Michael B.; Sandmaier, Brenda M.; Storer, Barry E.; Chauncey, Thomas; Stuart, Monic Jain; Maziarz, Richard; Agura, Edward; Langston, Amelia A.; Pulsipher, Michael; Storb, Rainer; Maloney, David G.

In: Blood, Vol. 104, No. 12, 01.12.2004, p. 3535-3542.

Research output: Contribution to journalArticle

Maris, MB, Sandmaier, BM, Storer, BE, Chauncey, T, Stuart, MJ, Maziarz, R, Agura, E, Langston, AA, Pulsipher, M, Storb, R & Maloney, DG 2004, 'Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma', Blood, vol. 104, no. 12, pp. 3535-3542. https://doi.org/10.1182/blood-2004-06-2275
Maris, Michael B. ; Sandmaier, Brenda M. ; Storer, Barry E. ; Chauncey, Thomas ; Stuart, Monic Jain ; Maziarz, Richard ; Agura, Edward ; Langston, Amelia A. ; Pulsipher, Michael ; Storb, Rainer ; Maloney, David G. / Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. In: Blood. 2004 ; Vol. 104, No. 12. pp. 3535-3542.
@article{b2ed8d8912ef4c30834019bea71481f1,
title = "Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma",
abstract = "We carried out HLA-matched related (n = 16) and unrelated (n = 17) hematopoietic cell transplantation (HCT) in 33 patients with relapsed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy total body irradiation. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil. Fourteen patients had failed high-dose autologous HCT. Of the 33 patients studied, 31 had stable engraftment, whereas 2 patients experienced nonfatal graft rejections. The incidences of acute grades II, III, and IV, and chronic graft-versus-host disease (GVHD) were 27{\%}, 17{\%}, 13{\%}, and 64{\%}, respectively. The overall response rate in the 20 patients with measurable disease at the time of HCT was 85{\%} (n = 17; 75{\%} complete remissions [CR] and 10{\%} partial remissions [PR]), whereas 3 patients had progressive disease. Only one of the 17 patients who responded and none of the 13 who received transplants in CR had disease relapse with a median follow-up of 24.6 months. Relapse and nonrelapse mortalities were 9{\%} and 24{\%}, respectively, at 2 years. The Kaplan-Meier probabilities of overall and disease-free survivals at 2 years were 65{\%} and 60{\%}, respectively. Allogeneic HCT after nonmyeloablative conditioning is a promising salvage strategy for patients with relapsed and refractory mantle cell lymphoma. The high response and low relapse rates with this approach suggest that mantle cell lymphoma is susceptible to graft-versus-tumor responses.",
author = "Maris, {Michael B.} and Sandmaier, {Brenda M.} and Storer, {Barry E.} and Thomas Chauncey and Stuart, {Monic Jain} and Richard Maziarz and Edward Agura and Langston, {Amelia A.} and Michael Pulsipher and Rainer Storb and Maloney, {David G.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1182/blood-2004-06-2275",
language = "English (US)",
volume = "104",
pages = "3535--3542",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

AU - Maris, Michael B.

AU - Sandmaier, Brenda M.

AU - Storer, Barry E.

AU - Chauncey, Thomas

AU - Stuart, Monic Jain

AU - Maziarz, Richard

AU - Agura, Edward

AU - Langston, Amelia A.

AU - Pulsipher, Michael

AU - Storb, Rainer

AU - Maloney, David G.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - We carried out HLA-matched related (n = 16) and unrelated (n = 17) hematopoietic cell transplantation (HCT) in 33 patients with relapsed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy total body irradiation. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil. Fourteen patients had failed high-dose autologous HCT. Of the 33 patients studied, 31 had stable engraftment, whereas 2 patients experienced nonfatal graft rejections. The incidences of acute grades II, III, and IV, and chronic graft-versus-host disease (GVHD) were 27%, 17%, 13%, and 64%, respectively. The overall response rate in the 20 patients with measurable disease at the time of HCT was 85% (n = 17; 75% complete remissions [CR] and 10% partial remissions [PR]), whereas 3 patients had progressive disease. Only one of the 17 patients who responded and none of the 13 who received transplants in CR had disease relapse with a median follow-up of 24.6 months. Relapse and nonrelapse mortalities were 9% and 24%, respectively, at 2 years. The Kaplan-Meier probabilities of overall and disease-free survivals at 2 years were 65% and 60%, respectively. Allogeneic HCT after nonmyeloablative conditioning is a promising salvage strategy for patients with relapsed and refractory mantle cell lymphoma. The high response and low relapse rates with this approach suggest that mantle cell lymphoma is susceptible to graft-versus-tumor responses.

AB - We carried out HLA-matched related (n = 16) and unrelated (n = 17) hematopoietic cell transplantation (HCT) in 33 patients with relapsed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy total body irradiation. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil. Fourteen patients had failed high-dose autologous HCT. Of the 33 patients studied, 31 had stable engraftment, whereas 2 patients experienced nonfatal graft rejections. The incidences of acute grades II, III, and IV, and chronic graft-versus-host disease (GVHD) were 27%, 17%, 13%, and 64%, respectively. The overall response rate in the 20 patients with measurable disease at the time of HCT was 85% (n = 17; 75% complete remissions [CR] and 10% partial remissions [PR]), whereas 3 patients had progressive disease. Only one of the 17 patients who responded and none of the 13 who received transplants in CR had disease relapse with a median follow-up of 24.6 months. Relapse and nonrelapse mortalities were 9% and 24%, respectively, at 2 years. The Kaplan-Meier probabilities of overall and disease-free survivals at 2 years were 65% and 60%, respectively. Allogeneic HCT after nonmyeloablative conditioning is a promising salvage strategy for patients with relapsed and refractory mantle cell lymphoma. The high response and low relapse rates with this approach suggest that mantle cell lymphoma is susceptible to graft-versus-tumor responses.

UR - http://www.scopus.com/inward/record.url?scp=9444239769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444239769&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-06-2275

DO - 10.1182/blood-2004-06-2275

M3 - Article

VL - 104

SP - 3535

EP - 3542

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -